Gene | CpG site | Gene section a,b | Percentage of significant iterations c | Median (IQR) P-value d | Direction of association e |
---|---|---|---|---|---|
CYP11A1 | cg23808031 | Promoter/ 1stExon | 100 | 2.8E-26 (1.8E-26–3.7E-26) | Harm |
POR | cg10738873 | 5'UTR | 100 | 2.2E-11 (1.7E-11–2.9E-11) | Harm |
cg17115737 | 5'UTR | 100 | 6.3E-13 (5.0E-13–8.1E-13) | Harm | |
cg27372063 | Body | 100 | 1.2E-24 (8.4E-25–1.5E-24) | Harm | |
CYB5A | cg18274065 | Promoter | 100 | 4.6E-29 (3.5E-29–6.4E-29) | Harm |
HSD17B1 | cg02363277 | Body | 100 | 1.7E-10 (1.4E-10–2.0E-10) | Harm |
HSD17B2 | cg09894383 | Promoter | 100 | 8.6E-40 (5.2E-40–1.2E-39) | Harm |
cg11515282 | Promoter | 100 | 8.3E-87 (4.7E-87–1.2E-86) | Harm | |
cg20373326 | Promoter | 100 | 1.9E-75 (1.2E-75–3.0E-75) | Harm | |
cg19807685 | 5'UTR/ 1stExon | 100 | 1.5E-37 (1.0E-37–2.0E-37) | Harm | |
cg26315602 | 1stExon | 100 | 8.1E-28 (5.6E-28–1.3E-27) | Harm | |
cg00365986 | Body | 100 | 6.4E-32 (4.3E-32–9.6E-32) | Harm | |
cg05315365 | Body | 100 | 2.6E-80 (1.6E-80–5.0E-80) | Harm | |
cg13740036 | Body | 100 | 2.5E-80 (1.6E-80–4.5E-80) | Harm | |
HSD17B3 | cg18014207 | Body | 100 | 1.3E-25 (9.3E-26–1.7E-25) | Harm |
HSD17B6 | cg21922731 | 5'UTR/ 1stExon | 100 | 8.7E-07 (6.6E-07–1.0E-06) | Harm |
HSD17B10 | cg26323797 | Promoter | 100 | 0.014 (0.013–0.016) | Harm |
HSD17B12 | cg14262884 | Body | 100 | 3.0E-20 (2.1E-20–4.2E-20) | Harm |
cg21077321 | Body | 100 | 7.3E-27 (5.6E-27–1.0E-26) | Harm | |
CYP19A1 | cg12009872 | Body | 100 | 4.5E-14 (3.3E-14–6.1E-14) | Harm |
cg14424631 | Body | 100 | 8.9E-07 (7.2E-07–1.0E-06) | Harm | |
CYP21A2 | cg11675917 | Promoter | 100 | 5.9E-09 (4.9E-09–6.8E-09) | Harm |
CYP11B2 | cg14389499 | Promoter | 100 | 4.7E-10 (3.8E-10–6.0E-10) | Harm |